Pascal Sati

Pascal Sati

Auto-generated profile, based on publicly available information

Pascal Sati

Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
EBErin S Beck
Erin S Beck
JMJosefina Maranzano
Josefina Maranzano
NLNicholas J Luciano
Nicholas J Luciano
PPPrasanna Parvathaneni
Prasanna Parvathaneni
SFStefano Filippini
Stefano Filippini
DRDaniel Reich
Daniel Reich
Background: Dramatic improvements in visualization of cortical (especially subpial) multiple sclerosis (MS) lesions allow assessment of impact on clinical course. Objective: Characterize cortical lesions by 7 tesla (T) T2*-/T1-weighted magnetic resonance imaging (MRI); determine relationship with other MS pathology and contribution to disability. Methods: Sixty-four adults with MS (45 relapsing–remitting/19 progressive) underwent 3 T brain/spine MRI, 7 T brain MRI, and clinical testing. Results: Cortical lesions were found in 94% (progressive: median 56/range 2–203; relapsing–remitting: 15/0–168; p = 0.004). Lesion distribution across 50 cortical regions was nonuniform ( p = 0.006), with highest lesion burden in supplementary motor cortex and highest prevalence in superior frontal gyrus. Leukocortical and white matter lesion volumes were strongly correlated ( r = 0.58, p < 0.0001), while subpial and white matter lesion volumes were moderately correlated ( r = 0.30, p = 0.002). Leukocortical ( p = 0.02) but not subpial lesions ( p = 0.40) were correlated with paramagnetic rim lesions; both were correlated with spinal cord lesions ( p = 0.01). Cortical lesion volumes (total and subtypes) were correlated with expanded disability status scale, 25-foot timed walk, nine-hole peg test, and symbol digit modality test scores. Conclusion: Cortical lesions are highly prevalent and are associated with disability and progressive disease. Subpial lesion burden is not strongly correlated with white matter lesions, suggesting differences in inflammation and repair mechanisms.

1 August 2024 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
ADAssunta Dal-Bianco
Assunta Dal-Bianco
JOJiwon Oh
Jiwon Oh
PSPascal Sati
Pascal Sati
MAMartina Absinta
Martina Absinta
In multiple sclerosis (MS), increasing disability is considered to occur due to persistent, chronic inflammation trapped within the central nervous system (CNS). This condition, known as smoldering neuroinflammation, is present across the clinical spectrum of MS and is currently understood to be relatively resistant to treatment with existing disease-modifying therapies. Chronic active white matter lesions represent a key component of smoldering neuroinflammation. Initially characterized in autopsy specimens, multiple approaches to visualize chronic active lesions (CALs) in vivo using advanced neuroimaging techniques and postprocessing methods are rapidly emerging. Among these in vivo imaging correlates of CALs, paramagnetic rim lesions (PRLs) are defined by the presence of a perilesional rim formed by iron-laden microglia and macrophages, whereas slowly expanding lesions are identified based on linear, concentric lesion expansion over time. In recent years, several longitudinal studies have linked the occurrence of in vivo detected CALs to a more aggressive disease course. PRLs are highly specific to MS and therefore have recently been incorporated into the MS diagnostic criteria. They also have prognostic potential as biomarkers to identify patients at risk of early and severe disease progression. These developments could significantly affect MS care and the evaluation of new treatments. This review describes the latest knowledge on CAL biology and imaging and the relevance of CALs to the natural history of MS. In addition, we outline considerations for current and future in vivo biomarkers of CALs, emphasizing the need for validation, standardization, and automation in their assessment.

23 March 2021 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
PDF file
JOJiwon Oh
Jiwon Oh
SSSuradech Suthiphosuwan
Suradech Suthiphosuwan
PSPascal Sati
Pascal Sati
MAMartina Absinta
Martina Absinta
BDBlake Dewey
Blake Dewey
AFAnthony Feinstein
Anthony Feinstein
The central vein sign (CVS) and “paramagnetic rim lesions” (PRL) are emerging imaging biomarkers in multiple sclerosis (MS) reflecting perivenular demyelination and chronic, smoldering inflammation. The objective of this study was to assess relationships between cognitive impairment (CI) and the CVS and PRL in radiologically isolated syndrome (RIS). Twenty-seven adults with RIS underwent 3.0 T MRI of the brain and cervical spinal cord (SC) and cognitive assessment using the minimal assessment of cognitive function in MS battery. The CVS and PRL were assessed in white-matter lesions (WMLs) on T2*-weighted segmented echo-planar magnitude and phase images. Multivariable linear regression evaluated relationships between CI and MRI measures. Global CI was present in 9 (33%) participants with processing speed and visual memory most frequently affected. Most participants (93%) had ⩾ 40% CVS + WML (a threshold distinguishing MS from other WM disorders); 63% demonstrated PRL. Linear regression revealed that CVS + WML predicted performance on verbal memory(β =-0.024, p = 0.03) while PRL predicted performance on verbal memory (β = -0.040, p = 0.04) and processing speed (β = -0.039, p = 0.03). CI is common in RIS and is associated with markers of perivenular demyelination and chronic inflammation in WML, such as CVS + WML and PRL. A prospective follow-up of this cohort will ascertain the importance of CI, CVS, and PRL as risk factors for conversion from RIS to MS.

14 September 2022 in NeuroImage: Clinical
Verified
Journal Article
Open access
HKHadar Kolb
Hadar Kolb
OAOmar Al-Louzi
Omar Al-Louzi
EBErin S. Beck
Erin S. Beck
PSPascal Sati
Pascal Sati
MAMartina Absinta
Martina Absinta
DRDaniel Reich
Daniel Reich
• MS white matter lesions are perivenular. The central vein sign (CVS) is a promising diagnostic biomarker with excellent sensitivity and specificity. • A subset of MS lesions, termed “chronic active,” shows persistent inflammatory demyelinating activity at the lesion edges. Their imaging correlate, “paramagnetic rim lesions” (PRL), can identify MS cases at risk for early disability accrual and progression. • PRL are specific for MS, however their diagnostic role requires more investigation. Pilot proof-of-concept clinical trials are now implementing PRL as outcome measures. • Imaging remyelination remains challenging, and no method has been accepted as a gold standard. At 7T, T1 times correlate with the degree of lesion myelination. • Cortical lesions are specific for MS and included in the current criteria for MS dissemination in space. Although cortical lesions have been associated with disease progression, their use is limited due to their difficult visualization in vivo, even with 7T MRI.

13 December 2023 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
LDLynn Daboul
Lynn Daboul
COCarly M O’dOnnell
Carly M O’dOnnell
MAMoein Amin
Moein Amin
PRPaulo Rodrigues
Paulo Rodrigues
JDJohn Derbyshire
John Derbyshire
DODaniel Ontaneda
Daniel Ontaneda
Background: The central vein sign (CVS) is a proposed magnetic resonance imaging (MRI) biomarker for multiple sclerosis (MS); the optimal method for abbreviated CVS scoring is not yet established. Objective: The aim of this study was to evaluate the performance of a simplified approach to CVS assessment in a multicenter study of patients being evaluated for suspected MS. Methods: Adults referred for possible MS to 10 sites were recruited. A post-Gd 3D T2*-weighted MRI sequence (FLAIR*) was obtained in each subject. Trained raters at each site identified up to six CVS-positive lesions per FLAIR* scan. Diagnostic performance of CVS was evaluated for a diagnosis of MS which had been confirmed using the 2017 McDonald criteria at thresholds including three positive lesions (Select-3*) and six positive lesions (Select-6*). Inter-rater reliability assessments were performed. Results: Overall, 78 participants were analyzed; 37 (47%) were diagnosed with MS, and 41 (53%) were not. The mean age of participants was 45 (range: 19–64) years, and most were female ( n = 55, 71%). The area under the receiver operating characteristic curve (AUROC) for the simplified counting method was 0.83 (95% CI: 0.73–0.93). Select-3* and Select-6* had sensitivity of 81% and 65% and specificity of 68% and 98%, respectively. Inter-rater agreement was 78% for Select-3* and 83% for Select-6*. Conclusion: A simplified method for CVS assessment in patients referred for suspected MS demonstrated good diagnostic performance and inter-rater agreement.

13 January 2022 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
OAOmar Al-Louzi
Omar Al-Louzi
VLVijay Letchuman
Vijay Letchuman
SMSargis Manukyan
Sargis Manukyan
EBErin S. Beck
Erin S. Beck
SRSnehashis Roy
Snehashis Roy
DRDaniel Reich
Daniel Reich
Background and Objectives The central vein sign (CVS), a central linear hypointensity within lesions on T2*-weighted imaging, has been established as a sensitive and specific biomarker for the diagnosis of multiple sclerosis (MS). However, the CVS has not yet been comprehensively studied in newly developing MS lesions. We aimed to identify the CVS profiles of new white matter lesions in patients with MS followed over time and investigate demographic and clinical risk factors associated with new CVS+ or CVS− lesion development. Methods In this retrospective longitudinal cohort study, adults from the NIH MS Natural History Study were considered for inclusion. Participants with new T2 or enhancing lesions were identified through review of the radiology report and/or longitudinal subtraction imaging. Each new lesion was evaluated for the CVS. Clinical characteristics were identified through chart review. Results A total of 153 adults (95 relapsing-remitting MS, 27 secondary progressive MS, 16 primary progressive MS, 5 clinically isolated syndrome, and 10 healthy; 67% female) were included. Of this cohort, 96 had at least 1 new T2 or contrast-enhancing lesion during median 3.1 years (Q1–Q3: 0.7–6.3) of follow-up; lesions eligible for CVS evaluation were found in 62 (65%). Of 233 new CVS-eligible lesions, 159 (68%) were CVS+, with 30 (48%) individuals having only CVS+, 12 (19%) only CVS−, and 20 (32%) both CVS+ and CVS− lesions. In gadolinium-enhancing (Gd+) lesions, the CVS+ percentage increased from 102/152 (67%) at the first time point where the lesion was observed, to 92/114 (82%) after a median follow-up of 2.8 years. Younger age (OR = 0.5 per 10-year increase, 95% CI = 0.3–0.8) and higher CVS+ percentage at baseline (OR = 1.4 per 10% increase, 95% CI = 1.1–1.9) were associated with increased likelihood of new CVS+ lesion development. Discussion In a cohort of adults with MS followed over a median duration of 3 years, most newly developing T2 or enhancing lesions were CVS+ (68%), and nearly half (48%) developed new CVS+ lesions only. Importantly, the effects of edema and T2 signal changes can obscure small veins in Gd+ lesions; therefore, caution and follow-up is necessary when determining their CVS status. Trial Registration Information Clinical trial registration number NCT00001248. Classification of Evidence This study provides Class III evidence that younger age and higher CVS+ percentage at baseline are associated with new CVS+ lesion development.